HopeStage
Back to all studies
CompletedEUCTR 2005-003180-23

An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...

This historical record does not confirm current site availability.

Historical research recordCzechiaAnxiety
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
Czechia
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
480
Sponsor
sanofi-aventis recherche & développement
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Czechia
Age range
Not clearly listed
Official registry ID
EUCTR 2005-003180-23
Official title
Show the full official title

An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Czechia

Registry details
Historical country statuses
FAQ

Questions about this study

Who is behind this study?

The study sponsor is sanofi-aventis recherche & développement.

Want to explore more studies?

Explore studies